Healthcare Services company Vimta Labs announced Q4FY26 & FY26 results Q4FY26 Financial Highlights: Total Income: Stood at Rs 1,120 million in Q4FY26, representing a growth of 11.5% QoQ from Rs 1,005 million in Q3FY26 and a 16.6% YoY increase from Rs 961 million in Q4FY25. EBITDA (including other income): Reached Rs 421 million, an increase of 22.3% QoQ from Rs 344 million and 21.5% YoY from Rs 347 million. EBITDA Margin: Improved to 37.6% in Q4FY26, compared to 34.3% in Q3FY26 and 36.1% in Q4FY25. Profit Before Tax (PBT): For continuing operations, PBT was Rs 290.47 million in Q4FY26, compared to Rs 250.27 million in Q4FY25. Profit After Tax (PAT): For continued operations, PAT stood at Rs 211 million, up 20.1% QoQ from Rs 176 million and 15.2% YoY from Rs 183 million. PAT Margin: Reported at 18.9% for the quarter. Basic EPS: Stood at Rs 4.7 for Q4FY26. FY26 Financial Highlights: Total Income: Reached Rs 4,163 million for the full year, a growth of 19.5% YoY from Rs 3,482 million in FY25. EBITDA: Reported at Rs 1,489 million, up 18.0% YoY from Rs 1,262 million in FY25. EBITDA Margin: Stood at 35.8% for the full year. Profit Before Tax (PBT): Including discontinued operations, PBT was Rs 1,039.53 million, compared to Rs 904.05 million in FY25. Profit After Tax (PAT): For continued operations, PAT reached Rs 775 million, marking a 16.1% YoY growth from Rs 668 million in FY25. PAT Margin: Stood at 18.6% for FY26. Basic EPS: Stood at Rs 17.4 for FY26. Business Highlights Segment Information: The company operates in only one reportable segment, namely "Contract Research and Testing Services". Growth Drivers: The strong annual performance was primarily driven by exceptional results in the Pharma and Food divisions. Dividend: The Board of Directors has recommended a final dividend of Rs 2 per share (100%) with a face value of Rs 2 each for the financial year 2025-26, subject to shareholder approval. International Expansion: The Board approved the proposal to incorporate a wholly owned subsidiary of the company in the USA. Bonus Issue: Following approval in June 2025, the company issued bonus shares in a 1:1 ratio, allotting 2,22,52,764 equity shares. Labour Code Impact: The company recognized a non-recurring incremental impact of past service cost in gratuity amounting to Rs 16.16 million due to new labour codes, which was recorded as an exceptional item in FY26. Executive Leadership: The Board approved the reappointment of Dr. S. P. Vasireddi as Executive Chairman for a five-year term effective from July 1, 2026. Divestment Note: The sale of the Diagnostic and Pathological services business to Thyrocare Technologies was completed in October 2024. The company continues to receive a Brand Royalty fee of 5% of the revenue from this business. Harita Vasireddi, Managing Director, Vimta Labs, said: "We are pleased to close this fiscal year on a strong note, achieving the highest-ever quarterly revenue of Rs. 1,120 Mn, up by 11.5% YoY. On a full-year basis, we crossed an important milestone and achieved a revenue of Rs. 4,163 Mn. These strong results were driven by the exceptional performance of our Pharma, and Food divisions. Sustained demand across sectors for high-quality research and testing services, coupled with the continued trust and confidence demonstrated by our customers, enabled us to deliver a strong EBITDA margin for the year. This performance underscores the strength of our diversified service portfolio, operational discipline, and customer-centric approach. As we move forward, we remain focused on expanding capabilities, investing in technology and talent, and strengthening long-term partnerships to drive sustainable growth and value creation for all stakeholders.” Result PDF